ArticleJournal of cancer research and clinical oncology2016

Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.

Kai Xue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.